Impact of Vutrisiran on Functional Capacity and Quality of Life in Transthyretin Amyloidosis With Cardiomyopathy
Vutrisiran maintained or improved functional capacity, health status, and QOL in more patients with ATTR-CM vs placebo over 30 months.
Authors
- Simone Longhi (ORCID: https://orcid.org/0000-0002-7512-1179)
- Chongshu Chen (ORCID: https://orcid.org/0000-0002-6013-4903)
- W.H. Wilson Tang (ORCID: https://orcid.org/0000-0002-8335-735X)
- Emre Aldinc (ORCID: https://orcid.org/0000-0002-7237-4760)
- Farooq H. Sheikh (ORCID: https://orcid.org/0000-0001-9687-9475)
- Julian D. Gillmore (ORCID: https://orcid.org/0000-0001-6174-9232)
- Ugochukwu Egolum (ORCID: https://orcid.org/0000-0002-9606-1347)
- Gilbert Habib (ORCID: https://orcid.org/0000-0003-3899-9983)
Institutions
- Cleveland Clinic (US)
- Alnylam Pharmaceuticals (United States) (US)
- Georgetown University (US)
- The Royal Free Hospital (GB)
- Amyloidosis Foundation (US)
- Azienda USL di Bologna (IT)
- MedStar Heart & Vascular Institute (US)
- Hôpital de la Timone (FR)
- University College London (GB)
Publication Details
- Journal
- Journal of the American College of Cardiology
- Published
- 2025-03-17
- DOI
- https://doi.org/10.1016/j.jacc.2025.03.454
- Citations
- 11
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 8.87
Funders
- Alnylam Pharmaceuticals